Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide

British Journal of Cancer

Volumn 75, Issue 11, 1997, Pages 1660-1666

  De Jong, R S ^a   Mulder, N H ^a   Uges, D R A ^a   Kaul, S ^b   Winograd, B ^b   Sleijfer, D Th ^a   Groen, H J M ^c   Willemse, P H B ^a   Van Der Graaf, W T A ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

^c Department of Neurology   (United Kingdom)

Author keywords

Etoposide; Etoposide phosphate; Oral; Pharmacokinetics; Toxicity

Indexed keywords

ANTINEOPLASTIC ALKALOID; ETOPOFOS; ETOPOSIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 8244260093     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.282     Document Type: Article

References (25)

1. Bosanquet AG and Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355-362
2. Budman DR, Igwemezie LN, Kaul S, Behr J, Lichtman S, Schulman P, Vinciguerra V, Allen SL, Kolitz J, Hock K, Oneill K, Schacter L and Barbhaiya RH (1994) Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumours. J Clin Oncol 12: 1902-1909
3. Chabot GG, Armand J-P, Terret M, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J and Bonnay M (1996) Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. J Clin Oncol 14: 2020-2030
4. Cockroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
5. Fields SZ, Igwemezie LN, Kaul S, Schacter LP, Schilder RJ, Litam PP, Himpler BS, McAleer C, Wright J, Barbhaiya RH, Langer CJ and O'Dwyer P (1995) Phase I study of etoposide phosphate (Etopophos) as a 30-minute infusion on days 1, 3, and 5. Clin Cancer Res 1: 105-111
6. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd edn, pp. 409-416. Marcel Dekker: New York
7. Hainsworth JD and Greco FA (1995). Etoposide: Twenty years later. Ann Oncol 6: 325-341
8. Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr M, Randolph J, Schacter L and Greco FA (1995) Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol 13: 1436-1442
9. Hande KR, Krozely MG, Greco FA, Hainsworth JD and Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374-377
10. Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A and Wrigley PFM (1985) Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21: 1315-1319
11. Hoskins PJ and Swenerton KD (1994) Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12: 60-63
12. Liu B, Earl HM, Poole CJ, Dunn J and Kerr DJ (1995) Etoposide binding in cancer patients. Cancer Chemother Pharmacol 36: 506-512
13. Martin M, Lluch A, Casado A, Santabarbara P, Androver E, Valverde JJ, Lopez-Martin JA, Rodriguez-Lescure A, Azagra P, Garcia-Conde J and Diaz-Rubio E (1994) Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 12: 986-991
14. Pflüger K-H, Hahn M, Holz J-B, Holz J-B, Schmidt, Köhl P, Fritsch H-W, Jungclas H and Haveman K (1993) Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 31: 350-356
15. Riegelman S and Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and adsorption time. J Pharmacokinet Biopharm 8: 509-534
16. Saulnier MG, Langley DR, Kadow JF, Senter PD, Knipe JO, Tun MM, Vyas DM and Doyle TW (1994) Synthesis of etoposide phosphate, BMY-40481: a water-soluble clinically active prodrug of etoposide. Bioorg Med Chem Lett 4: 2567-2572
17. Sessa C, Zuchetti M, Cerny T, Pagani O, Cavalli F, De Fusco M, De Jong J, Gentili D, McDaniel C, Prins C, Schacter L, Winograd B and D'Incalci M (1995) Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13: 200-209
18. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH and Wrigley PFM (1989a) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340
19. Slevin ML, Joel SP and Whomsley R (1989b) The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24: 329-331
20. Stewart CF, Arbuck SG, Pieper JA and Evans WE (1989) Altered protein binding in patients with cancer. Clin Pharmacol Ther 45: 49-55
21. Stewart CF, Fleming RA, Arbuck SG and Evans WF (1990) Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50: 6854-6856
22. Stewart CF, Arbuck SG, Fleming RA and Evans WE (1991) Relation of systemic exposure to unbound etoposide and haematologic toxicity. Clin Pharmacol Ther 50: 385-393
23. Wagner T and Fenneberg K (1984) Bioavailability of cyclophosphamide from oral formulations. Eur J Clin Pharmacol 26: 269-270
24. World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment, Nijhoff: The Hague, The Netherlands
25. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B and Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl Med Med 308: 1005-1009